Robbins P F, el-Gamil M, Li Y F, Topalian S L, Rivoltini L, Sakaguchi K, Appella E, Kawakami Y, Rosenberg S A
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
J Immunol. 1995 Jun 1;154(11):5944-50.
The role of tumor-specific T cells in mediating the regression of metastatic melanoma has been suggested by the clinical response of patients to treatment with tumor-infiltrating lymphocytes (TIL). A number of Ags recognized by class I-restricted melanoma-specific T cells have recently been isolated, raising the hope that this will lead to the development of improved therapies. In this study, we report the cloning of a tumor Ag recognized by T cells from melanoma patient 888. Previously, we reported that TIL 888, grown from the tumor of this patient, recognized tyrosinase in an HLA-A24-restricted fashion. This line, when infused into the autologous patient, resulted in complete regression of multiple metastases. Three years later, a second TIL line, TIL 1290, was isolated from a recurrent pelvic tumor. Infusion of a mixture of TIL 888 and TIL 1290 cell lines into the patient resulted in complete regression of a residual abdominal mass and the patient remains disease-free 2 yr later. The TIL 1290 cell line, which recognized melanoma in an HLA-A24-restricted manner, failed to recognize tyrosinase. TIL 1290 was then used to screen an 888 melanoma cDNA library, and an Ag was isolated that did not correspond to any found in sequence databases. This gene, termed p15, was found to be expressed in a variety of normal tissues, and a peptide epitope recognized by TIL 1290 was found to represent the product of an nonmutated gene. Screening of additional cDNA pools resulted in the isolation of a second clone which stimulated TIL 1290. This clone also appeared to represent a transcript of the p15 gene, indicating that this gene may encode the predominant Ag recognized by TIL 1290.
肿瘤浸润淋巴细胞(TIL)治疗患者的临床反应提示了肿瘤特异性T细胞在介导转移性黑色素瘤消退中的作用。最近已分离出一些由I类限制性黑色素瘤特异性T细胞识别的抗原,这使人们希望这将导致改进疗法的开发。在本研究中,我们报告了从黑色素瘤患者888的T细胞中克隆出一种肿瘤抗原。此前,我们报道从该患者肿瘤中培养的TIL 888以HLA - A24限制性方式识别酪氨酸酶。该细胞系注入自体患者后,导致多处转移灶完全消退。三年后,从复发性盆腔肿瘤中分离出第二个TIL细胞系TIL 1290。将TIL 888和TIL 1290细胞系的混合物注入患者后,残余腹部肿块完全消退,且患者在2年后仍无疾病。以HLA - A24限制性方式识别黑色素瘤的TIL 1290细胞系不能识别酪氨酸酶。然后用TIL 1290筛选888黑色素瘤cDNA文库,分离出一种与序列数据库中任何已知序列均不对应的抗原。该基因称为p15,发现在多种正常组织中表达,并且发现TIL 1290识别的一个肽表位代表一个非突变基因的产物。对其他cDNA文库的筛选导致分离出第二个刺激TIL 1290的克隆。该克隆似乎也代表p15基因的转录本,表明该基因可能编码TIL 1290识别的主要抗原。